Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

The firm, known for its focus on software, is going to start throwing more money at the hardware behind AI.

Andreessen Horowitz has two partners sitting on the boards of companies that now compete with each other: Ben Horowitz at Databricks and Martin Casado at Fivetran. Nothing too scandalous on the surface, except the Department of Justice has reportedly been investigating the arrangement for almost a year, dusting off a 112-year-old antitrust law that’s rarely used against VCs.  Board conflicts aren’t exactly new, and these companies weren’t necessarily direct competitors when a16z first invested […]